SCHEMBL12892140

SCHEMBL12892140

COC(=O)CC(c1cnc2c(c1)CCCC2)C1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
GPR119 Q8TDV5 10/20 0.41
DPP4 P27487 1/20 0.39
MMP13 P45452 5/20 0.38
EED O75530 1/20 0.38
RBBP4 Q09028 1/20 0.38
SUZ12 Q15022 1/20 0.38
EZH2 Q15910 1/20 0.38
AEBP2 Q6ZN18 1/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPT P10636 1/20 0.38
MAPK1 P28482 1/20 0.38
HTT P42858 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MMP1 P03956 3/20 0.37
MMP3 P08254 3/20 0.37
MMP7 P09237 3/20 0.37
MMP9 P14780 3/20 0.37
MMP8 P22894 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8345834 0.91 NPC1 (0.40) NPC1RAB9AGPR119DPP4MMP13
SCHEMBL8345088 0.86 ITGB3 (0.48) NPC1RAB9AGPR119KDM4EPKM
SCHEMBL13855088 0.86 ITGB3 (0.48) NPC1RAB9AGPR119KDM4EPKM
SCHEMBL10154213 0.83 P2RX7 (0.36) NPC1RAB9AALDH1A1MAPTKDM4E
SCHEMBL12892122 0.80 ITGB3 (0.45) NPC1RAB9AGPR119MMP13EED
SCHEMBL13855089 0.78 ITGB3 (0.56) NPC1RAB9AGPR119KDM4EPKM
SCHEMBL13591240 0.76 ALDH1A1 (0.51) NPC1RAB9AGPR119ALDH1A1MAPT
SCHEMBL5940502 0.76 MMP13 (0.52) NPC1RAB9AGPR119DPP4MMP13
SCHEMBL12892175 0.74 GPR119 (0.44) NPC1RAB9AGPR119DPP4ALDH1A1
SCHEMBL2904902 0.74 ITGB3 (0.66)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8110683-B2 Piperidinyl compounds that selectively bind integrins JANSSEN PHARMACEUTICA N.V. (BE) 2012-02-07 US disclosed
US-20110092528-A1 PIPERIDINYL COMPOUNDS THAT SELECTIVELY BIND INTEGRINS DE CORTE BART 2011-04-21 US disclosed
US-7879881-B2 1-[[3-[(1,4,5,6-Tetrahydro-2-pyrimidinyl)amino]phenyl]acetyl]-4-piperidinepropanoic acid; new class of selective modulator of beta 3, beta 5 or dual integrin receptors; anticarcinogenic, antiinflammatory, antidiabetic agent JANSSEN PHARMACEUTICA NV (BE) 2011-02-01 US disclosed
US-7879881-B2 1-[[3-[(1,4,5,6-Tetrahydro-2-pyrimidinyl)amino]phenyl]acetyl]-4-piperidinepropanoic acid; new class of selective modulator of beta 3, beta 5 or dual integrin receptors; anticarcinogenic, antiinflammatory, antidiabetic agent JANSSEN PHARMACEUTICA NV (BE) 2011-02-01 US disclosed
US-20080058359-A1 Piperidinyl compounds that selectively bind integrins JANSSEN PHARMACEUTICA, N.V. (BE) 2008-03-06 US disclosed
US-20080058359-A1 Piperidinyl compounds that selectively bind integrins JANSSEN PHARMACEUTICA, N.V. (BE) 2008-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058359-A1 Piperidinyl compounds that selectively bind integrins ITGB3, ITGAV, ITGA2B NPC1 1817/4885RAB9A 1193/4885GPR119 1579/4885
US-20110092528-A1 PIPERIDINYL COMPOUNDS THAT SELECTIVELY BIND INTEGRINS ITGB3, ITGAV, ITGA2B NPC1 1817/4885RAB9A 1193/4885GPR119 1579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.